MIRA Pharmaceuticals, Inc. - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. MIRA Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule therapeutics for neuropathic pain, inflammatory pain, weight management, and addiction. The company operates as a single segment and is classified as a smaller reporting company and an emerging growth company. As of May 14, 2026, there were 42,022,087 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,150,152) | $(1,783,779) |
| Loss Per Share (Basic/Diluted) | $(0.03) | $(0.11) |
| Operating Expenses | $1,103,479 | $1,805,200 |
| Cash and Cash Equivalents (End of Period) | $4,815,031 | $1,206,285 |
| Short-Term Investments | $4,591,518 | $4,683,099 |
| Total Current Liabilities | $114,761 | $702,068 |
| Accumulated Deficit | $(40,730,358) | $(30,921,500) |
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately $634,000 (36%) compared to Q1 2025, driven primarily by a significant reduction in General and Administrative (G&A) expenses.
- G&A Expense Decline: G&A expenses dropped from $1.49 million to $0.58 million. This decrease is attributed to a $0.8 million reduction in stock-based compensation and lower payroll-related expenses.
- R&D Expense Increase: Research and Development expenses increased by $210,000 (67%) to $0.52 million, primarily due to increased development costs for the MIRA-55 candidate and pre-IND submission work.
- Liability Reduction: Total current liabilities decreased significantly from $702,068 to $114,761, largely due to the repayment of a $330,607 advance payable to a related party during the quarter.
- Equity Method Loss: The company recognized a $91,582 loss from its equity method investment in Telomir Pharmaceuticals, Inc., which was not present in the prior year period.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the 12 months following the filing date. The company does not have sufficient cash to fund operations for that period without additional financing.
- Liquidity Runway: Management currently expects existing cash and equivalents to fund operations into the first quarter of 2027, though this is contingent on successful capital raising.
- Pipeline Progress:
- Ketamir-2: Completed Phase 1 trials; preparing for Phase 2a in chemotherapy-induced peripheral neuropathy (CIPN) in the first half of 2026.
- MIRA-55: Preclinical studies for inflammatory pain showed analgesic effects without CNS side effects; advancing toward IND-enabling studies.
- SKNY-1: Acquired via merger in late 2025; preclinical candidate for weight management and addiction. Preclinical data showed reductions in body weight and nicotine-seeking behavior.
- Capital Needs: The company plans to seek additional capital through public/private equity offerings, strategic alliances, or debt. Failure to secure funding may require curtailing operations.
- Related Party Transactions: Significant transactions involve related parties, including the acquisition of SKNY Pharmaceuticals, license agreements with MIRALOGX, and repayment of advances from the CEO.
Investor Verification Checklist
- Verify the company's ability to secure additional financing given the explicit "substantial doubt" regarding going concern status.
- Confirm the timeline and regulatory feedback for the initiation of the Ketamir-2 Phase 2a trial in H1 2026.
- Review the valuation and performance of the equity method investment in Telomir Pharmaceuticals (approx. 10% ownership).
- Monitor the status of the Executive Incentive Compensation Plan (EICP) and potential future stock-based compensation expenses.
- Assess the impact of the recent SKNY acquisition on the company's cash burn rate and R&D pipeline diversification.